deltatrials
Unknown PHASE3 INTERVENTIONAL 1-arm NCT00583193

Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder

A Study of the Effectiveness and Tolerability of Duloxetine (Cymbalta) in the Treatment of PTSD.

Sponsor: Canive, Jose M., M.D.

Conditions Posttraumatic Stress Disorders
Interventions Duloxetine hydrochloride
Updated 5 times since 2017 Last updated: Dec 20, 2007 Started: Dec 31, 2005 Completion: Jun 30, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00583193, this PHASE3 trial focuses on Posttraumatic Stress Disorders and remains ongoing. Sponsored by Canive, Jose M., M.D., it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotUnknown Status~Feb 2017 – ~Jan 2021 · 47 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 24 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE3

  4. Feb 2017 — Jan 2021 [monthly]

    Unknown Status PHASE3

  5. Jan 2017 — Feb 2017 [monthly]

    Unknown Status PHASE3

    First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Canive, Jose M., M.D.
  • Eli Lilly and Company
Data source: New Mexico VA Healthcare System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations